Skip to main
PRTA

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Prothena Corp PLC has a promising clinical pipeline focused on treating neurodegenerative and rare diseases, particularly through its antibody-based product candidates, which have shown a favorable reduction in amyloid levels in various dosing studies. The company has guided the potential to earn up to $105 million in aggregate milestones by 2026, primarily from partnerships with Novo Nordisk and Bristol-Myers Squibb, which underscores its strategic collaborations and revenue-generating potential. Despite some safety concerns related to elevated ARIA incidence in specific treatments, overall tolerability remains favorable, positioning Prothena Corp well for future growth in the biotechnology sector.

Bears say

Prothena Corp faces a negative outlook primarily due to ongoing net losses projected to continue until at least product approval and commercialization, necessitating additional capital raises that may dilute shareholder value. The uncertainties surrounding regulatory approvals increase risks for the company's pipeline of investigational therapeutics, which includes candidates targeting serious conditions like amyloidosis and neurodegenerative diseases. Furthermore, the recent findings regarding elevated ARIA levels with strong amyloid reduction in PRX012 highlight clinical risks that may hinder the successful development and commercialization of its product candidates.

Prothena (PRTA) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 9 analysts, Prothena (PRTA) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.